There are no articles in this category. If subcategories display on this page, they may contain articles.
Continued steady growth of Tuzistra® XR annualised prescription run rate through drug's second cough cold season; similar growth rate expected for 2017/18 season
More information on Vernalis and its pipeline ...
Company fact sheet
Explore the pipeline ...
T: 0118 938 0000 F: 0118 938 0001Contact informationMaps and directionsContact form
To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and firstname.lastname@example.org or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch